Investing News NetworkYour trusted source for investing success

Videos
Companies
Press Releases
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Private Placements
Trending
Trending Articles

Could the Silver Price Really Hit US$100 per Ounce? (Updated 2024)

How Would a New BRICS Currency Affect the US Dollar? (Updated 2024)

Top 10 Countries for Natural Gas Production (Updated 2024)

Top 10 Copper-producing Companies (Updated 2024)

7 Biggest Lithium-mining Companies

Top 7 Canadian Lithium Stocks of 2024

11 Canadian Cryptocurrency ETFs (Updated 2024)

Where Does Tesla Get its Lithium? (Updated 2024)

Hydrogen Stocks: 9 Biggest Companies

Trending Press Releases

Galan Lithium Limited (ASX: GLN) – Trading Halt

Edison Lithium Expands Portfolio with Acquisition of Additional Sodium Brine Claim in Saskatchewan

Bitcoin Well Launches Cash Vouchers For Canadian Customers

Sona Nanotech Provides Interim Results of Dalhousie Efficacy Study

Osisko Metals Reports Preliminary Metallurgical Testwork Results From Gaspé Copper

Mineral Resource Update – Mt Boppy Gold Project

More Press Releases
Trending Companies

Ramp Metals

RAMP:CC

Galan Lithium

GLN:AU

Trident Royalties PLC

TDTRF

Purpose Bitcoin ETF

BTCC:CA
More Companies
Trending Reports

2024 EV Market Outlook Report

2024 Lithium Market Outlook

2024 Uranium Outlook (Updated for Q2)

2024 Gold Outlook Report

More Outlook Reports
Resource
Resource
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Tech
Tech
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Life Science
Life Science
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Gold
Copper
Uranium
Oil and Gas
Artificial Intelligence
Biotech
loader

Aurinia Pharmaceuticals

NASDAQ:AUPH
Press Releases

Aurinia Files Form S-8 to Register Shares Underlying Previously Disclosed Inducement Awards for Newly Hired Employees

Aurinia Announces 2023 Annual General Meeting Results

Aurinia Pharmaceuticals Announces Kidney Biopsies Sub-study Data from the LUPKYNIS® AURORA 2 Clinical Trial Presented at Congress of Clinical Rheumatology East Conference

Aurinia is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. In January 2021 the Company introduced the first FDA-approved oral therapy indicated for the treatment of adult patients with active lupus nephritis LN. Aurinias head office is in Victoria British Columbia; its U.S. commercial hub is in Rockville Maryland; and the Company focuses development efforts globally. Follow us on Twitter at @AuriniaPharma and on LinkedIn.
×